The U.S. Food and Drug Administration (FDA) has issued a warning about the potential risk of mental health side effects associated with certain asthma medications. The alert specifically focuses on the use of leukotriene inhibitors, a class of drugs commonly prescribed for asthma management.
According to the FDA, leukotriene inhibitors, which include popular drugs such as montelukast (brand name Singulair), have been linked to various mental health side effects. These may include changes in mood, behavior, or thinking, such as depression, anxiety, aggression, hallucinations, suicidal thoughts, and even completed suicides.
While the exact mechanism behind these side effects remains unclear, the FDA urges healthcare professionals, caregivers, and patients to be vigilant when taking or administering these medications. It is important to monitor for any unusual or concerning changes in mental health and report them promptly to a healthcare provider.
FDA approval of the first drug for NASH treatment
The FDA is working closely with the manufacturers of leukotriene inhibitors to update the prescribing information with a strengthened warning about the risk of mental health side effects. This will provide healthcare professionals and patients with clearer information to make informed decisions regarding asthma treatment options.
It is worth noting that asthma medications should not be abruptly discontinued without consulting a healthcare professional. The benefits of these drugs in managing asthma symptoms should be weighed against the potential risks of mental health side effects on an individual basis.
Patients and healthcare professionals are encouraged to report any adverse reactions or side effects associated with leukotriene inhibitors or any other medication to the FDA’s MedWatch program. This allows the FDA to continuously monitor the safety and efficacy of drugs in the market.
As more information becomes available, the FDA will provide updates and further guidance to ensure the safe use of asthma medications.
